What did @miriamand7 actually say?
Honestly? Not much, medically speaking. The video's audio is entirely lyrics from Don McLean's "American Pie," covering lines about "the day the music died" and driving to a levy that "was dry." There are no spoken claims about semaglutide, dosing, weight loss timelines, or health outcomes. The medical messaging here is entirely visual and contextual, carried by the hashtags #semaglutide and #rybelsusweightloss rather than anything the creator says out loud. That matters, because the implied claim is still a claim: this is a before-and-after or transformation video tied to a prescription drug, and viewers are making inferences based on what they see, not what they hear.
The hashtag #cambiofisico translates from Spanish as "physical change" or "body transformation," which tells us the creator is documenting a physical result they attribute, at least loosely, to semaglutide or Rybelsus specifically.
Does the science back this up?
The general premise, that semaglutide produces meaningful weight loss, is well-supported. But transformation videos skip every part of the story that actually matters for a viewer considering this medication.
Semaglutide works as a GLP-1 receptor agonist, slowing gastric emptying and acting on hypothalamic satiety pathways to reduce appetite. In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), adults without diabetes using 2.4mg weekly subcutaneous semaglutide lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. That is a real, clinically significant effect. Rybelsus, the oral formulation shown in the hashtags, is approved at up to 14mg daily, primarily for type 2 diabetes, and its weight loss data is more modest than injectable Wegovy.
The problem is that individual results vary substantially. Some participants in STEP trials lost over 20% of body weight. Others lost under 5%. A TikTok transformation does not tell you where you will land on that curve.
What did they get wrong (or right)?
The creator did not get anything factually wrong in their spoken content, because they did not make any spoken factual claims. That is both the defense and the problem. Associating a dramatic physical transformation with a prescription drug hashtag, without any context, implies that the drug alone caused the result and that similar results are typical or expected. That implication is misleading even if no single sentence is technically false.
What they got right, indirectly: semaglutide does produce real physical changes in many people. The drug is legitimate, FDA-approved, and backed by large randomized controlled trial data. Documenting a personal result is not inherently irresponsible.
What is missing is everything else. No mention of side effects, which in the SUSTAIN and STEP trials included nausea in roughly 44% of participants, vomiting, diarrhea, and in rarer cases pancreatitis risk. No acknowledgment that Rybelsus and injectable semaglutide are different formulations with different efficacy profiles. No context about whether diet, exercise, or other interventions were part of the result shown.
What should you actually know?
If you found this video and are considering semaglutide, here is what the research actually says, not what a transformation clip implies.
- Semaglutide is a prescription medication. In the US, Rybelsus is approved for type 2 diabetes management, not weight loss. Wegovy (subcutaneous 2.4mg weekly) is approved for chronic weight management in adults with obesity or overweight plus a weight-related condition.
- Results are not uniform. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained weight loss over two years, but individual variation is wide. Genetics, baseline metabolic health, adherence, and lifestyle all affect outcomes.
- Compounded semaglutide is not the same as brand-name Wegovy or Rybelsus. Compounded versions are not FDA-approved and have not gone through the same manufacturing or efficacy review process. Do not assume equivalency.
- Stopping the drug typically reverses the weight loss. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that participants regained about two-thirds of lost weight within a year of discontinuation. This is a long-term management tool, not a one-time fix.
- Side effects are common and sometimes serious. Anyone starting semaglutide should do so under medical supervision with a full review of their history, including personal or family history of medullary thyroid carcinoma or MEN2 syndrome, which are contraindications.
Transformation content can motivate people to ask their doctor a question they might not have asked. That is the best-case read. The worst case is that viewers walk away thinking a single drug produces a guaranteed, photogenic result with no tradeoffs. The truth is somewhere more complicated, and more honest, than a TikTok hashtag allows.